- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Abivax S.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mo | EQS-News: ABIVAX: Abivax Announces a Change to the Composition of its Board of Directors | 400 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Personnel
Abivax Announces a Change to the Composition of its Board of Directors
23.12.2024 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| 04.12. | Why ABIVAX Société Anonyme (ABVX) is the Best All-Time Low Stock to Buy Right Now? | 33 | Insider Monkey | ||
| 19.11. | EQS-News: ABIVAX: Abivax Establishes an At-the-Market (ATM) Program on Nasdaq | 442 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Establishes an At-the-Market (ATM) Program on Nasdaq
19.11.2024 / 22:30 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| 15.11. | Abivax reports liqyuduty position | 23 | Seeking Alpha | ||
| ABIVAX SA ADR Aktie jetzt für 0€ handeln | |||||
| 14.11. | EQS-News: ABIVAX: Abivax presents third quarter 2024 key financial information | 533 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Quarter Results
Abivax presents third quarter 2024 key financial information
14.11.2024 / 22:01 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| 14.11. | Abivax S.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 13.11. | Abivax ernennt Branchenveteran Mark Stenhouse zum Berater | 8 | Investing.com Deutsch | ||
| 13.11. | Abivax appoints industry veteran Mark Stenhouse as advisor | 3 | Investing.com | ||
| 13.11. | EQS-News: ABIVAX: Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax | 350 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Personnel
Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax
13.11.2024 / 22:01 CET/CEST
The... ► Artikel lesen | |
| 11.10. | ABIVAX Announces Termination of Liquidity Contract and Publishes End of Contract Statement | 567 | Dow Jones News | DJ ABIVAX Announces Termination of Liquidity Contract and Publishes End of Contract Statement.
ABIVAX
ABIVAX Announces Termination of Liquidity Contract and Publishes End of Contract Statement.... ► Artikel lesen | |
| 07.10. | EQS-News: ABIVAX: Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation | 487 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Miscellaneous
Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional... ► Artikel lesen | |
| 03.10. | Abivax Aktie: Durchbruch in Colitis-Studie beflügelt Kursfantasie | 889 | Börse Global | Das französische Biotech-Unternehmen Abivax vermeldet positive Ergebnisse aus seiner langfristigen Studie zur Behandlung von Colitis ulcerosa. Patienten, die über einen Zeitraum von bis zu sechs Jahren... ► Artikel lesen | |
| 03.10. | EQS-News: ABIVAX: Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease | 478 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Study
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease
03.10.2024 / 22:01 CET/CEST
The... ► Artikel lesen | |
| 03.10. | Abivax: Neue Studiendaten | 507 | 4investors | Das französische Biotech-Unternehmen Abivax publiziert neue Daten einer Phase IIa/b Studie zur Behandlung von Colitis ulcerosa. Dabei wurden Patienten mit 25mg Obefazimod einmal täglich behandelt. Die... ► Artikel lesen | |
| 03.10. | Abivax S.A. - 6-K, Report of foreign issuer | 8 | SEC Filings | ||
| 03.10. | EQS-News: ABIVAX: Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance | 473 | EQS Group (EN) | EQS-News: ABIVAX
/ Key word(s): Study/Study results
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative... ► Artikel lesen | |
| 30.09. | Guggenheim hält an Kaufempfehlung für Abivax fest und bestätigt Kursziel | 34 | Investing.com Deutsch | ||
| 26.09. | Piper Sandler maintains price target on Abivax, optimistic on obefazimod | 9 | Investing.com | ||
| 26.09. | Piper Sandler hält an 42-US-Dollar-Kursziel für Abivax fest und bleibt optimistisch für Obefazimod | 17 | Investing.com Deutsch |
Seite:
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 30,040 | +3,19 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2024 Financial Results and Provides Business Updates | - Final positive safety and efficacy findings from CORE-001 study of Cretostimogene Grenadenorepvec in combination with Pembrolizumab in BCG-Unresponsive NMIBC simultaneously published online by Nature... ► Artikel lesen | |
| QUANTUM-SI | 3,575 | +66,28 % | Pre-market Movers: Intrusion, SES AI, Solid Power, Quantum-Si, Rail Vision | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green Intrusion Inc. (INTZ) is up over 380% at $2.16.
SES... ► Artikel lesen | |
| QIAGEN | 43,310 | +0,69 % | Biotech Report: Qiagen und Evotec leichter | (shareribs.com) Frankfurt / New York 20.12.2024 - Zum Ende der letzten Handelswoche des Jahres stehen die Biotechwerte unter Druck. Im deutschen Handel geht es für Evotec und Qiagen abwärts.Der DAX... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,390 | -3,52 % | Is Recursion Pharmaceuticals Stock a Millionaire Maker? | ||
| TEMPUS AI | 35,120 | -0,48 % | Cathie Woods ARK kauft AMD und TEMPUS AI, verkauft ARCHER AVIATION | ||
| NUVALENT | 80,30 | -2,14 % | Nuvalent-Direktor Shair verkauft Aktien im Wert von 167.565 US-Dollar | ||
| EVOTEC | 8,535 | +1,49 % | Aixtron, Evotec, Nagarro, Redcare Pharmacy, SMA Solar, TUI u.a. - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 55,00 | +1,20 % | How Tarsus Pharmaceuticals' Unique Inspiration Is Driving A Triple-Digit Run | ||
| DYNE THERAPEUTICS | 23,720 | -3,06 % | Dyne Therapeutics Reports Positive Data From Phase 1/2 DELIVER Trial Of DYNE-251 In DMD | WASHINGTON (dpa-AFX) - Tuesday, Dyne Therapeutics, Inc. (DYN) revealed new clinical findings from its Phase 1/2 DELIVER trial of DYNE-251 for patients with Duchenne muscular dystrophy also known... ► Artikel lesen | |
| BIONTECH | 109,40 | -0,18 % | Biontech und Pfizer zahlen für Vergleich in USA | MAINZ (dpa-AFX) - Der Impfstoffhersteller Biontech hat in den USA im Streit um Lizenzgebühren millionenschwere Vergleiche geschlossen. Insgesamt umgerechnet 1,2 Milliarden Euro werden das Unternehmen... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 10,790 | -3,23 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates | Commercial launch of neffy® (epinephrine nasal spray) underway in the United StatesSupplemental NDA for neffy®1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025Exclusive... ► Artikel lesen | |
| CELCUITY | 13,840 | +5,81 % | Celcuity (NASDAQ:CELC) Trading Up 3.8% - Here's Why | ||
| HUMACYTE | 5,500 | +3,97 % | Humacyte (NASDAQ:HUMA) Shares Up 6% - Here's What Happened | ||
| RELAY THERAPEUTICS | 4,360 | -2,02 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival | New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 8,870 | -3,27 % | Pre-market Movers: Loop Industries, Repare Therapeutics, Candel Therapeutics, Inovio Pharmaceuticals, iSpecimen | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.35 A.M. ET).In the Green Loop Industries, Inc. (LOOP) is up over 56% at $1.93.
iSpecimen... ► Artikel lesen |
ABIVAX SA ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,01 % bei einem Aktienkurs von 6,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ABIVAX SA ADR finden Sie auf Wallstreet Online.
